Cited by 343Dermatology and Skin DiseasesAsthma and respiratory diseasesPsoriasis: Treatment and Pathogenesis

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Dupilumab: A review of its use in the treatment of atopic dermatitis

Gooderham, Melinda J., Hong, H. Chih-ho, Eshtiaghi, Panteha, Papp, Kim A.·2018·Journal of the American Academy of Dermatology

DOI 10.1016/j.jaad.2017.12.022

Open this paper in CoChat — free account

Abstract

Atopic dermatitis (AD) is a chronic, pruritic immune-mediated inflammatory dermatosis characterized by a T helper 2 (Th2) immune response phenotype and may be associated with systemic inflammation. Dupilumab is an interleukin 4 (IL-4) receptor α-antagonist that inhibits IL-4 and IL-13 signaling through blockade of the shared IL-4α subunit. Blockade of IL-4/13 is effective in reducing Th2 response. Dupilumab has recently been approved in the United States and Europe for the treatment of adult patients with moderate-to-severe AD. Clinical trials have shown that adults with moderate-to-severe AD who receive weekly or biweekly dupilumab injections have significantly improved clinical and patient-reported outcomes, including Eczema Area Severity Index, SCORing Atopic Dermatitis, Dermatology Life Quality Index, and itch Numeric Rating Scale scores. Concomitant use of topical corticosteroids along with dupilumab results in a greater improvement in signs and symptoms of AD than with use of dupilumab alone. Biomarker analyses show that dupilumab modulates the AD molecular signature and other Th2-associated biomarkers. Common adverse events reported in the clinical trials were nasopharyngitis, upper respiratory tract infection, injection site reactions, skin infections, and conjunctivitis. These were mild-to-moderate in nature, and overall rates of adverse events occurred with similar frequency between the treatment and placebo groups. There were no significant serious safety concerns identified in phase III clinical trials. Dupilumab, as monotherapy or with concomitant use of topical corticosteroids, can significantly improve clinical outcomes and quality of life in patients suffering from moderate-to-severe AD. Ongoing studies of dupilumab will help determine the clinical efficacy and safety profile of its long-term use.

Integrity signals

Registry

Crossref · 10.1016/j.jaad.2017.12.022

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M. H., Bieber, T. R. M., Rocklin, R. E., Ming, J. E., Ren, H., Kao, R., Simpson, E. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,435
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Blauvelt, A., de Bruin-Weller, M. S., Gooderham, M., Cather, J. C., Weisman, J. D., Pariser, D. M., Simpson, E. L., Papp, K. A., Hong, H.-K., Rubel, D. M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31191-1 · Cited by 1,282
Self-citation
Eczema Prevalence in the United States: Data from the 2003 National Survey of Children's Health
Shaw, T., Currie, G. P., Koudelka, C. W., & Simpson, E. L. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.251 · Cited by 721
The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
Brunner, P. M., Guttman‐Yassky, E., & Leung, D. Y. M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.011 · Cited by 662
Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity
Kakinuma, T., Nakamura, K., Wakugawa, M., Mitsui, H., Tada, Y., Saeki, H., Torii, H., Asahina, A., Onai, N., Matsushima, K., et al. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.113237 · Cited by 574
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
Thaçi, D., Simpson, E. L., Beck, L. A., Bieber, T. R. M., Blauvelt, A., Papp, K. A., Soong, W., Worm, M., Szepietowski, J. C., Sofen, H. L., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00388-8 · Cited by 573
Self-citation
Commonality of the IL-4/IL-13 pathway in atopic diseases
Gandhi, N. A., Pirozzi, G., & Graham, N. M. H. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1298443 · Cited by 493
Deciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches
Leung, D. Y. M., & Guttman‐Yassky, E. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.08.008 · Cited by 486
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis
Hamilton, J. D., Suárez‐Fariñas, M., Dhingra, N., Cardinale, I. R., Li, X., Kostić, A., Ming, J. E., Radin, A. R., Krueger, J. G., Graham, N. M. H., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.10.013 · Cited by 472

Flagged first, then by citations

Show all 17 references

Sorted by citations

Items 101–200 of 341

Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study
Veverka, K. A., Thng, S. T. G., Silverberg, J. I., Armstrong, A. W., Menezes, J., Kaoukhov, A., & Blauvelt, A. (2023) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.10.026 · Cited by 20
Use of Dupilumab in the Treatment of Papuloerythroderma of Ofuji
Teraki, Y., TAGUCHI, R., Takamura, S., & Fukuda, T. (2019) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.0946 · Cited by 19
Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing.
Johnson, H. (2022) · Current Psychiatry · doi:10.12788/cutis.0519 · Cited by 20
Atopic Dermatitis: The Relationship Between Immune Mediators and Skin Lipid Barrier
You, H., & Liang, Y. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09057-y · Cited by 17
“As a fully human monoclonal antibody, dupilumab inhibits IL-4/IL-13 signaling by competitively targeting the shared subunit IL-4Rα [229].”
Exogenous drug-induced mouse models of atopic dermatitis
Zheng, R., Ren, Y., Liu, X., He, C., Liu, H., Wang, Y., Li, J., Xia, S., Liu, Z., Ma, Y., et al. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.01.003 · Cited by 18
Unraveling the link between atopic dermatitis and autoimmune diseases in children: Insights from a large-scale cohort study with 15-year follow-up and shared gene ontology analysis
Ahn, J., Shin, S., Lee, G. C., Han, B. E., Lee, E. M., Ha, E. K., Shin, J., Lee, W. S., Kim, J. H., & Han, M. Y. (2024) · Allergology International · doi:10.1016/j.alit.2023.12.005 · Cited by 18
Atopic dermatitis treatment: A comprehensive review of conventional and novel bioengineered approaches
Elahi, N., Astaneh, M. E., Ai, J., & Rizwan, M. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.137083 · Cited by 22
Molecular mechanism of asthma and its novel molecular target therapeutic agent
Suraya, R., Nagano, T., Katsurada, M., Sekiya, R., Kobayashi, K., & Nishimura, Y. (2021) · Respiratory Investigation · doi:10.1016/j.resinv.2020.12.007 · Cited by 18
The efficacy and safety of JAK inhibitors for atopic dermatitis: a systematic review and meta-analysis
Miao, M., & Ma, L. (2021) · Journal of Dermatological Treatment · doi:10.1080/09546634.2021.1942422 · Cited by 18
“Biologics that inhibit cytokine signaling have been found to be effective in the treatment of AD (39).”
Background
Vaccinations in Selected Immune-Related Diseases Treated with Biological Drugs and JAK Inhibitors—Literature Review and Statement of Experts from Polish Dermatological Society
Narbutt, J., Żuber, Z. M., Lesiak, A., Bień, N., & Szepietowski, J. C. (2024) · Vaccines · doi:10.3390/vaccines12010082 · Cited by 21
IL-13 Controls IL-33 Activity through Modulation of ST2
Zhang, M., Duffen, J., Nocka, K. H., & Kasaian, M. T. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100655 · Cited by 18
Vaccination Recommendations for Psoriasis and Atopic Dermatitis Patients on Biologic Therapy: A Practical Guide.
Fan, R., & Cohen, J. M. (2022) · PubMed Central · Cited by 17
Interdisziplinäre Handlungsempfehlung bei Dupilumab-assoziierten entzündlichen Augenerkrankungen
Wohlrab, J., Wollenberg, A., Reimann, H., Pleyer, U., & Werfel, T. (2018) · Der Hautarzt · doi:10.1007/s00105-018-4316-1 · Cited by 17
Therapeutical Targets in Allergic Inflammation
Salvati, L., Liotta, F., Annunziato, F., & Cosmi, L. (2022) · Biomedicines · doi:10.3390/biomedicines10112874 · Cited by 15
IgE levels in patients with atopic dermatitis steadily decrease during treatment with dupilumab regardless of dose interval
Dekkers, C., van der Wal, M., van den Noort, L., Bakker, D. S., de Bruin-Weller, M. S., & van Wijk, F. (2023) · Clinical & Experimental Allergy · doi:10.1111/cea.14384 · Cited by 16
MONOCLONAL ANTIBODY THERAPIES for Atopic Dermatitis: Where Are We Now in the Spectrum of Disease Management?
Rosso, J. Q. D. (2019) · Europe PMC (PubMed Central) · Cited by 16
Treatment Guidelines for Atopic Dermatitis Since the Approval of Dupilumab: A Systematic Review and Quality Appraisal Using AGREE-II
Ghazal, S., Ridha, Z., D’Aguanno, K., Nassim, D., Quaiattini, A., Netchiporouk, E., Poulin, Y. P., Kalia, S., Marcoux, D., Piguet, V., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.821871 · Cited by 15
Atopic Dermatitis Mediates the Association Between an IL4RA Variant and Food Allergy in School-Aged Children
Banzon, T. M., Kelly, M. S., Bartnikas, L. M., Sheehan, W. J., Cunningham, A., Harb, H., Crestani, E., Valeri, L., Greco, K. F., Chatila, T. A., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.04.042 · Cited by 15
Management of contact dermatitis
Dickel, H. (2023) · Allergo Journal International · doi:10.1007/s40629-023-00246-9 · Cited by 15
Increased Regulatory T Cells and Decreased Myeloid-Derived Suppressor Cells Induced by High CCL17 Levels May Account for Normal Incidence of Cancers among Patients with Atopic Dermatitis
Morimura, S., Sugaya, M., Oka, T., Suga, H., Miyagaki, T., Tsunemi, Y., Asano, Y., & Sato, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042025 · Cited by 15
Comprehensive analysis of human IL‐4 receptor subunits shows compartmentalization in steady state and dupilumab treatment
Heeb, L. E. M., & Boyman, O. (2022) · Allergy · doi:10.1111/all.15576 · Cited by 15
The Future of Asthma Care
Holgate, S. T., Walker, S. M., West, B., & Boycott, K. (2019) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2018.10.013 · Cited by 18
Brief Academic Review and Clinical Practice Guidelines for Pediatric Atopic Dermatitis
Yang, Y. B., Gohari, A., & Lam, J. M. (2020) · Current Pediatric Reviews · doi:10.2174/1573396316999200820163434 · Cited by 15
Real-World Effectiveness of Newly Initiated Systemic Therapy for Atopic Dermatitis in the United States: A Claims Database Analysis
Wu, J. J., Lafeuille, M., Émond, B., Fakih, I., Duh, M. S., Cappelleri, J. C., Yin, N. C., Feeney, C., Myers, D. E., & DiBonaventura, M. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02197-z · Cited by 14
“The systemic AD treatments considered were based on American Academy of Dermatology clinical guidelines and reviews of treatments for moderate-to-severe AD [10, 13].”
Background
Dupilumab as promising treatment for prurigo nodularis: current evidences
Toffoli, L., Farinazzo, E., Zelin, E., Agozzino, M., Dianzani, C., di Meo, N., Nan, K., Zalaudek, I., & Conforti, C. (2021) · Journal of Dermatological Treatment · doi:10.1080/09546634.2021.1886232 · Cited by 14
“Other promising targets in PN therapy are the IL-4 and IL-13, which are inhibited by dupilumab, a monoclonal antibody approved for the treatment of atopic dermatitis.”
BackgroundInfluential
T-bet and STAT6 Coordinately Suppress the Development of IL-9–Mediated Atopic Dermatitis–Like Skin Inflammation in Mice
Makita, S., Takatori, H., Matsuki, A., Kawashima, H., Iwata, A., Tanaka, S., Nakagomi, D., Oya, Y., Matsumura, R., Tamachi, T., et al. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.08.029 · Cited by 14
Biological Tipping Point in Patients with Atopic Dermatitis Treated with Different Dosing Intervals of Dupilumab
Dekkers, C., van der Wal, M., Amrani, M. E., van Luin, M., Bakker, D. S., de Bruin-Weller, M. S., & van Wijk, F. (2023) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2023.03.1659 · Cited by 13
Drug Survival, Retention, and Persistence of Dupilumab in Adults and Adolescents with Atopic Dermatitis: A Narrative Literature Review
Rossi, M., Ferrucci, S. M., Calzavara‐Pinton, P., Marzano, A. V., Peris, K., Nicoli, E., Moretti, D., & Chiricozzi, A. (2024) · Advances in Therapy · doi:10.1007/s12325-024-03052-z · Cited by 14
T2-associated diseases: focus on the comorbid patient
Кузубова, Н. А., & Titova, O. N. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-17-57-64 · Cited by 14
Acquired hypersensitivity to dupilumab: first case report
Ludriksone, L., Elsner, P. U., & Schliemann, S. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15807 · Cited by 13
Dupilumab-induced Eosinophilic Granulomatosis with Polyangiitis Complicated by Peripheral Neuropathic Pain: a Case Report and Literature Review
Wu, J., Li, L., Ten, W., Wang, Y., Liu, R., Hu, B., Tan, J., Dong, F., Shi, K., Zhang, H., et al. (2025) · Journal of Clinical Immunology · doi:10.1007/s10875-025-01914-x · Cited by 12
Pruritogenic Mediators and New Antipruritic Drugs in Atopic Dermatitis
Koumaki, D., Gregoriou, S., Evangelou, G., & Krasagakis, K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062091 · Cited by 13
Evaluation of Leukocytes, B and T Lymphocytes, and expression of CD200 and CD23 on B lymphocytes in Patients with Atopic Dermatitis on Dupilumab Therapy—Pilot Study
Čelakovská, J., Čermáková, E., Boudková, P., Andrýs, C., & Krejsek, J. (2023) · Dermatology and Therapy · doi:10.1007/s13555-023-00918-y · Cited by 12
“Clinical trials have shown that adults with moderate-to-severe AD who receive weekly or biweekly dupilumab injections have significantly improved clinical and patient-reported outcomes, including Eczema Area Severity Index, SCORing Atopic Dermatitis, Dermatology Life Quality Index, and Itch Numeric Rating Scale scores…”
Background
Review of health economic analyses in atopic dermatitis: how diverse is the literature?
Gutknecht, M., Reinert, R., & Augustin, M. (2018) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2019.1549491 · Cited by 12
“Dupilumab as monotherapy or in addition with topical corticosteroids has demonstrated its efficacy in clinical and patientreported outcomes without significant safety concerns [17,21].”
Background
Drug survival rates and reasons for drug discontinuation in patients with atopic dermatitis: a retrospective study of adult outpatients
Lopez, J. P., Kromer, C., Herr, R. M., Schmieder, A., Bayerl, C., & Schaarschmidt, M. (2021) · European Journal of Dermatology · doi:10.1684/ejd.2021.4020 · Cited by 12
Biological treatment in allergic disease
Shamji, M. H., Palmer, E. N., Layhadi, J. A., Moraes, T. J., & Eiwegger, T. (2021) · Allergy · doi:10.1111/all.14954 · Cited by 12
IL‐4/IL‐13 pathway in nasal type 2 inflammation: The central role and targeted therapy
Zhu, Z., Zhao, C., & Wang, M. (2024) · Eye & ENT Research · doi:10.1002/eer3.5 · Cited by 11
Stratum Corneum Biomarkers in Atopic Dermatitis: Biological and Spatial Variability
Tončić, R. J., Kežić, S., Hadžavdić, S. L., Marinović, B., & Jakaša, I. (2020) · The Open Biomarkers Journal · doi:10.2174/1875318302010010047 · Cited by 11
Adverse effects of dupilumab in chronic rhinosinusitis with nasal polyps. Case report and narrative review
Nitro, L., Bulfamante, A. M., Rosso, C., Saibene, A. M., Arnone, F., Felisati, G., & Pipolo, C. (2022) · Acta Otorhinolaryngologica Italica · doi:10.14639/0392-100x-n1911 · Cited by 12
Erythema, pruritus, and diffuse peeling of skin during dupilumab therapy for atopic dermatitis in three adults
Hammadi, A. A., & Parmar, N. V. (2018) · International Journal of Dermatology · doi:10.1111/ijd.14296 · Cited by 11
Dupilumab probably reduces transepidermal water loss but does not increase stratum corneum hydration in atopic dermatitis
Furuhashi, T., Oda, T., Torii, K., Nishida, E., & Morita, A. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15638 · Cited by 14
Review of Tralokinumab in the Treatment of Atopic Dermatitis
Singh, R., Taylor, A., Shah, M. A., Strowd, L. C., & Feldman, S. R. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280221105686 · Cited by 10
Drug Survival and Predictors of Systemic Treatment Outcome in Atopic Dermatitis: Data From a Nationwide Swedish Cohort
Jonsson, P., Tayefi, M., Svedbom, A., Bradley, M., & Johansson, E. K. (2025) · Acta Dermato Venereologica · doi:10.2340/actadv.v105.43464 · Cited by 10
“Dupilumab inhibits interleukin 4 (IL-4) and IL-13 signalling – both important mediators of the type-2 immune response – by targeting the shared IL-4α subunit (8).”
Improve the dupilumab therapy evaluation with dermoscopy and high‐frequency ultrasound in moderate‐to‐severe atopic dermatitis
Liu, Z., Niu, Z., Zhang, D., Liu, J., & Zhu, Q. (2022) · Skin Research and Technology · doi:10.1111/srt.13260 · Cited by 10
The Usefulness of Line-Field Confocal Optical Coherence Tomography in Monitoring Epidermal Changes in Atopic Dermatitis in Response to Treatment: A Pilot Study
Dryżałowska, Z., Blicharz, L., Michalczyk, A., Kościan, J., Maj, M., Czuwara, J., & Rudnicka, L. (2024) · Diagnostics · doi:10.3390/diagnostics14161724 · Cited by 10
Six cases of refractory pruritus and histologic dermal hypersensitivity reaction successfully treated with dupilumab
Edmonds, N. L., Noland, M. M., & Flowers, R. H. (2021) · JAAD Case Reports · doi:10.1016/j.jdcr.2021.10.030 · Cited by 10
“Side effects have been reported with dupilumab therapy including injection site reaction, 162 conjunctivitis, and upper respiratory tract infections.(4) In this case series, one patient experienced 163”
Background
Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review
Lytvyn, Y., Mufti, A., Abduelmula, A., Sachdeva, M., Maliyar, K., Georgakopoulos, J. R., & Yeung, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112452 · Cited by 10
Patch Testing in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Multicentric Approach in Spain
Docampo‐Simón, A., Sánchez‐Pujol, M. J., Pastor‐Nieto, M. A., Giménez‐Arnau, A. M., Serna, M. R., Serra‐Baldrich, E., Miquel, J., Sánchez-Pérez, J., Sanz‐Sánchez, T., Zaragoza‐Ninet, V., et al. (2023) · Dermatitis · doi:10.1089/derm.2022.0023 · Cited by 9
“9 In addition, dupilumab has been used with acceptable efﬁcacy in refractory ACD involving individuals sensitized to a wide variety of allergens.”
Influential
T helper 22 cells from Han Chinese patients with atopic dermatitis exhibit high expression of inducible T‐cell costimulator
Jiao, Q., Qian, Q., Liu, C., Luo, Y., Fang, F., Wang, M., Ji, J. H., Qian, H., Zhang, X., & Maurer, M. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18040 · Cited by 10
Dual biologic therapy in a patient with severe asthma and other allergic disorders
Caskey, J., & Kaufman, D. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-242211 · Cited by 10
Distinct Proteomic Profiling of Plasma Extracellular Vesicles from Moderate-to-Severe Atopic Dermatitis Patients
Chang, C., Wang, H., Zhang, J., Zou, Y., Zhang, Y., Chen, J., Chen, C., Chung, W.-H., & Ji, C. (2021) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s325515 · Cited by 10
“It is also characterized by a T helper 2 (Th2) immune response phenotype.(1) AD has a substantial physical and psychosocial impact on patients and relatives.”
Background
Letter in reply: Linear IgA bullous dermatosis treated with dupilumab in a pediatric patient with glucose-6-phosphate dehydrogenase deficiency
Muzumdar, S., Bibb, L. A., Sloan, B., Murphy, M. J., & Chang, M. W. (2023) · JAAD Case Reports · doi:10.1016/j.jdcr.2023.11.025 · Cited by 9
Exploring the Complexities of Atopic Dermatitis: Pathophysiological Mechanisms and Therapeutic Approaches
Chaudhary, F., Lee, W., Eskandar, T., & Agrawal, D. K. (2024) · Journal of Biotechnology and Biomedicine · doi:10.26502/jbb.2642-91280155 · Cited by 9
“The JAK-STAT pathway is the system that is downstream of these receptors [38].”
Background
A risk-scoring system to predict dupilumab-associated ocular surface disease in patients with atopic dermatitis
Shim, S., Kim, J. S., Yee, J., & Gwak, H. S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1425550 · Cited by 9
Case report: Dupilumab: a promising treatment option for adult linear IgA bullous dermatosis with severe pruritus
Wang, L., Peng, J. P., & Chen, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1409556 · Cited by 9
Differential Diagnosis and Treatment of Itching in Children and Adolescents
Kang, S. Y., Um, J., Chung, B. Y., Kim, J. C., Park, C. W., & Kim, H. O. (2021) · Biomedicines · doi:10.3390/biomedicines9080919 · Cited by 11
Dupilumab-induced ocular surface disease: a primer
Reji, M. A., Haque, A., Goyal, S., & Krishnaswamy, G. A. (2022) · BMJ Case Reports · doi:10.1136/bcr-2022-249019 · Cited by 9
Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis
Nezamololama, N., Crowley, E. L., Gooderham, M., & Papp, K. A. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1804854 · Cited by 9
Self-citation
Influence of dupilumab on the economic burden of severe asthma and atopic dermatitis
Сергеевич, К. И., Сергеевна, К. В., Karpov, O. I., & Ermakova, V. Y. (2020) · Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · doi:10.37489/2588-0519-2020-3-15-26 · Cited by 9
Biological medication in atopic dermatitis
Fölster‐Holst, R., Torrelo, A., Das, K., Murrell, D. F., Patil, A. D., Rokni, G. R., Grabbe, S., Staubach, P., Sohn, A., & Goldust, M. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2026920 · Cited by 9
“cantly improve clinical outcomes and quality of life in patients suffering from moderate-to-severe atopic dermatitis [1].”
Background
S1‐Leitlinie Kontaktekzem
Dickel, H., Bauer, A., Brehler, R., Mahler, V., Merk, H. F., Neustädter, I., Strömer, K., Werfel, T., Worm, M., & Geier, J. (2022) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14734_g · Cited by 9
Treatments for chronic pruritus outside of the box
Metz, M. (2019) · Experimental Dermatology · doi:10.1111/exd.14007 · Cited by 9
Allergen immunotherapy and dupilumab in atopic dermatitis: Clinical efficacy and disparities in immunological indicators
Jin, L., Yang, L., Xu, Q., Jiang, Q., Huang, N., Li, W., Yang, Y., Ma, D., Li, L., Fu, Y., et al. (2025) · World Allergy Organization Journal · doi:10.1016/j.waojou.2025.101043 · Cited by 8
“14 , 15 Furthermore, allergen immunotherapy (AIT) is the only etiological treatment capable of inducing long-term immune tolerance in allergic diseases.”
Prurigo crónico: actualización
Docampo‐Simón, A., Sánchez‐Pujol, M. J., & Salvador, J. F. S. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2021.11.002 · Cited by 8
The use of dupilumab in patients with HIV
Edmonds, N. L., Zhao, P., & Flowers, R. H. (2022) · International Journal of STD & AIDS · doi:10.1177/09564624221129406 · Cited by 8
Peripheral blood mononuclear cell- transcriptome signatures of atopic dermatitis and prediction for the efficacy of dupilumab
Wang, Y., Wu, Y., Gu, C., Wang, S., Yin, H., Zhu, R., Wang, C., Li, Z., Yao, X., & Li, W. (2023) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2023.06.002 · Cited by 9
Dupilumab induced ocular surface disease: A prospective case series
Pradhan, S. P., Sadiq, S. N., Cartes, C., Babakinejad, P., Ball, S., Reynolds, N. J., Meggitt, S. J., & Figueiredo, F. C. (2023) · European Journal of Ophthalmology · doi:10.1177/11206721231199155 · Cited by 9
“17 Owing to this mechanism of action this drug has emerged as a targeted biologic treatment for AD but also for other suspected type-2 helper T cell mediated in ﬂ am-matory conditions like chronic rhinosinusitis with nasal polyps and uncontrolled persistent asthma.”
Background
Head and neck dermatitis: a variant of atopic dermatitis
Blicharz, L., Michalczyk, A., Maj, M., Czuwara, J., Olszewska, M., & Rudnicka, L. (2025) · Italian Journal of Dermatology and Venereology · doi:10.23736/s2784-8671.25.08001-6 · Cited by 9
Dupilumab as treatment for atopic dermatitis in a pediatric heart transplant patient: A case report
Jamgochian, M., Milgraum, D. M., Milgraum, S., & Pappert, A. S. (2020) · Dermatologic Therapy · doi:10.1111/dth.14018 · Cited by 8
“ment for children 6 to 11 years old prior to recent approval in that age group.(6,7) There are some case reports of dupilumab being used with success in heart transplant recipients older than 18 years of age,”
Background
Real‐world experience of dupilumab in the treatment of moderate‐to‐severe atopic dermatitis
Kim, N. S., Maliyar, K., de Oliveira, L. M., O’Toole, A., & Gooderham, M. (2020) · International Journal of Dermatology · doi:10.1111/ijd.15053 · Cited by 8
Self-citation
Candidate Gene Association Studies in Atopic Dermatitis in Participants of European and Asian Ancestry: A Systematic Review and Meta-Analysis
Pontikas, A., Antonatos, C., Evangelou, E., & Vasilopoulos, Y. (2023) · Genes · doi:10.3390/genes14071456 · Cited by 11
Bioinformatics Integrative Analysis of Circadian Rhythms Effects on Atopic Dermatitis and Dendritic Cells
Sun, N., Dai, D., Deng, S., Cai, X., & Song, P. (2023) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s424343 · Cited by 7
“33 In AD patients, circadian rhythm disturbances affect the secretion of cortisol, disrupt melatonin levels and worsen barrier function at night, resulting in an aggravated inflammatory response and the natural rhythm of immune cells and inflammatory cytokines.”
Background
Residual facial erythema in atopic dermatitis patients treated with dupilumab stratified by machine learning
Ashizaki, K., Ishikawa, T., & Nomura, Y. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19909 · Cited by 7
Lichen Simplex Chronicus: Clinical Perspectives and Emerging Therapeutic Strategies
Moshkovich, M., Andrade, L. F., Anderson, M., & Yosipovitch, G. (2025) · American Journal of Clinical Dermatology · doi:10.1007/s40257-025-00979-z · Cited by 7
“Dupilumab, a monoclonal antibody targeting interleukin-4 and interleukin-13 pathways, has demonstrated efficacy in reducing pruritus and inflammation in various chronic skin conditions including PN and AD [75, 76].”
The protective effects of human milk components, 2′-fucosyllactose and osteopontin, against 2,4-dinitrochlorobenzene-induced atopic dermatitis in mice
Chen, X., Yang, C., Zeng, J., Zhu, Z., Zhang, L., Lane, J. A., Wu, X., & Zuo, D. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104806 · Cited by 7
Anti-Inflammatory Effect of Cinnamaldehyde in a Mouse Model of 2,4-Dinitrofluorobenzene-Induced Atopic Dermatitis
Ustaoğlu, E., Türkoğlu, Z., Ulgen, O. A., Çaytemel, C., & Ağırgöl, Ş. (2023) · Indian Journal of Dermatology · doi:10.4103/ijd.ijd_576_22 · Cited by 7
“[14] Therefore, the investigation for treatment with high efficacy and low side effect profile continues.”
Advancements in pharmacological interventions for atopic dermatitis current strategies and future directions
Zhang, Y., Yuan, S., Wu, Y., Nie, W., You, T., Yang, H., & Liu, B. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01659-4 · Cited by 8
Efficacy and safety of dupilumab in patients with moderate-to-severe bullous pemphigoid: a systematic review and meta-analysis
da Silva, J. O. N., Silva, R. R. E., Ribeiro, P. V. Z., Farah, P. M. E., & Steglich, R. B. (2025) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2024.08.008 · Cited by 7
Genetically engineered drugs for treatment of bronchial asthma: recent achievements
Zyryanov, S. K., & Butranova, O. I. (2018) · PULMONOLOGIYA · doi:10.18093/0869-0189-2018-28-5-584-601 · Cited by 7
Dupilumab‐induced Urticaria
Mastorino, L., Ortoncelli, M., Virginia, B., Rolla, G., Avallone, G., Cavaliere, G., Viola, R., Quaglino, P., & Ribero, S. (2021) · Dermatologic Therapy · doi:10.1111/dth.15117 · Cited by 7
“It is a fully human monoclonal antibody that inhibits IL-4 and IL-13 signaling by blocking the shared receptor subunit IL4Rα reducing the T-helper-2 immune response.(2) Ocular surface disease, injection-site reactions, and recurrent oral herpes are well-known side effects of the atopic patient treated with dupilumab.”
Background
Dupilumab-associated ulcerative keratitis
Wilson, M., & Daniell, M. D. (2022) · International Journal of Ophthalmology · doi:10.18240/ijo.2022.06.23 · Cited by 7
Diagnosing mycosis fungoides after initiation of therapy with dupilumab: a case report and literature review
Yan, D., Ramachandran, V., Weston, G. K., Kim, R. H., & Latkowski, J.-A. M. (2023) · International Journal of Dermatology · doi:10.1111/ijd.16641 · Cited by 7
Two cases of dupilumab‐induced vitiligo
Ferreirinha, A., Farinha, P. S., Costa, T. P. E., & Duarte, B. (2024) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.15564 · Cited by 6
In vitro and in vivo evaluation of chemically synthesized, receptor-biased interleukin-4 and photocaged variants
Ninomiya, M., Egholm, C., Breu, D., Boyman, O., & Bode, J. W. (2025) · Science Advances · doi:10.1126/sciadv.adw9755 · Cited by 5
“Dupilumab, an anti–IL-4R α monoclonal antibody, blocks IL-4R–mediated signaling and was approved for atopic dermatitis in 2017 and for asthma in 2018 by the Food and Drug Administration ( 18 – 20 ).”
Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study
Silverberg, J. I., Ackerman, L., Bagel, J., Gold, L. S., Blauvelt, A., Rosmarin, D. M., Chovatiya, R., Zirwas, M., Yosipovitch, G., Waibel, J. S., et al. (2026) · Dermatology and Therapy · doi:10.1007/s13555-025-01644-3 · Cited by 6
Treatment of Severe Atopic Dermatitis with Dupilumab in Three Patients with Renal Diseases
Foti, C., Romita, P., Ambrogio, F., Manno, C., Filotico, R., Cassano, N., Vena, G. A., MARCO, A. D., Cazzato, G., & Mennuni, B. G. (2022) · Life · doi:10.3390/life12122002 · Cited by 6
“Dupilumab is a human monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling by binding the shared alpha-subunit of the IL-4 receptor, thus reducing the Th2 response [1].”
Background
Safety and effectiveness of dupilumab in the real‐world treatment of atopic dermatitis in Japan: 1‐year interim analysis from a post‐marketing surveillance
Saeki, H., Fujita, H., Suzuki, K., & Arima, K. (2023) · Journal of Cutaneous Immunology and Allergy · doi:10.1002/cia2.12303 · Cited by 6
Dupilumab in Patients with Atopic Dermatitis: A Multicentric, Long-Term, Real-World Portuguese Study
Torres, T. R., Cruz, M. J., Gonçalo, M., Filipe, P., Duarte, B., Alves, J., Alvarenga, J. M., da Rosa, G. P., Flor, D., Ramos, J. A., et al. (2024) · Dermatology and Therapy · doi:10.1007/s13555-024-01235-8 · Cited by 6
Efficacy and safety of dupilumab in a patient with metastatic clear cell renal cell carcinoma
Ferreira, C., Freitas, E., & Torres, T. R. (2024) · Journal of International Medical Research · doi:10.1177/03000605241297551 · Cited by 6
Atopic Dermatitis in Adults: Epidemiology, Risk Factors, Pathogenesis, Clinical Features, and Management
Oninla, O. A., Akinkugbe, A., Otike-Odibi, B. I., Oripelaye, M. M., & Olanrewaju, F. O. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97287 · Cited by 6
Efficacy and safety of baricitinib for the treatment of moderate‐to‐severe atopic dermatitis: A systematic review and meta‐analysis of randomized clinical trials
Wang, B., Pan, S.-X., Yao, Y.-P., Zeng, L.-X., & Zhang, G. (2022) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13704 · Cited by 7
“Dupilumab, the first biologic approved as a first-line treatment for moderate-to-severe AD, is an interleukin (IL)-4 receptor antagonist that inhibits IL-4 and IL-13 signalling and showed promising efficacy.(7) Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway (JAK–STAT pathway) ar…”
Background
Interleukin-18 as a severity marker and novel potential therapeutic target for epidermolytic ichthyosis
Ansai, O., Miyauchi, T., Hayashi, R., Katsumi, T., Nishiguchi, T., Hasegawa, A., Shinkuma, S., Natsuga, K., Nomura, T., Shimomura, Y., et al. (2022) · Clinical and Experimental Dermatology · doi:10.1093/ced/llac069 · Cited by 6
Dupilumab for treatment of severe atopic dermatitis accompanied by lichenoid amyloidosis in adults: Two case reports
Zhao, X.-Q., Zhu, W.-J., Mou, Y., Meng, X., & Xia, J. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i10.2301 · Cited by 6
Therapy of Allergic and Irritant Contact Dermatitis
Ludriksone, L., Antonov, D., Schliemann, S., & Elsner, P. U. (2020) · Springer eBooks · doi:10.1007/978-3-030-36335-2_72 · Cited by 7
Atopic keratoconjunctivitis alleviated with dupilumab
Chen, J., & Bielory, L. (2022) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2022.05.031 · Cited by 6
Serum Mediators in Patients with Both Type 2 Diabetes Mellitus and Pruritus
He, G.-Y., Hsu, T.-Y., Chen, C.-W., Nien, F., Chen, H., Chu, C., & Wang, L. (2023) · Acta Dermato Venereologica · doi:10.2340/actadv.v103.4863 · Cited by 5
“Dupilumab, an IL4Rα antibody targeting IL4 and IL13, has been shown to have a significant effect on itching relief in AD, prurigo nodularis, and many pruritic skin disorders (22, 23).”
Background
A Case Report and Literature Review of the Role of Dupilumab in the Management of Lichen Planus: Cause or Treatment?
Gajraj, F. A., Zahir, J., Adereti, C. O., & Gajraj, M. H. (2023) · Cureus · doi:10.7759/cureus.41274 · Cited by 5
“Dupilumab is a monoclonal antibody, commonly used to treat severe AD, which targets the interleukin(IL)-4 receptor alpha subunit (4Rα) found on T-helper cells type 2 (TH2); IL4Rα normally interacts with IL-4 and IL-13 [9].”
Background
Exploring causal correlations between circulating cytokines and atopic dermatitis: a bidirectional two-sample Mendelian randomization study
Xuan, Z., Chen, X., Zhou, W., Shen, Y., Sun, Z., Zhang, H., & Yao, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1367958 · Cited by 5
“Notably, the approval of dupilumab, an antagonist of IL-4 and IL-13, for treating patients with moderate-to-severe AD exempli ﬁ es this promising approach (41).”
Background
Inadequate response and treatment patterns in adults diagnosed with atopic dermatitis and treated with topical therapy
Gorritz, M., Boytsov, N. N., Goldblum, O. M., Malatestinic, W. N., Wang, X., & Wade, R. L. (2021) · Journal of Dermatological Treatment · doi:10.1080/09546634.2021.1981813 · Cited by 5
Anti‐pruritic effect of isothiocyanates: Potential involvement of toll‐like receptor 3 signaling
Moriyama, M., Konno, M., Serizawa, K., Yuzawa, N., Majima, Y., Hayashi, I., Suzuki, T., & Kainoh, M. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1038 · Cited by 4

Authors: Gooderham, M. J., Hong, H. C.-H., Eshtiaghi, P., & Papp, K. A.
Affiliations: Queen's University (CA)
University of British Columbia (CA)
Probity Medical Research (CA)
Corresponding author: Gooderham, Melinda J.
ORCID: Gooderham, Melinda J.
Hong, H. Chih-ho
Eshtiaghi, Panteha
Papp, Kim A.
Venue: Journal of the American Academy of Dermatology
Publisher: Elsevier BV
Published: 2018-03
Volume: 78
Issue: 3
Pages: S28-S36
ISSN: 0190-9622 (ISSN-L)
DOI: 10.1016/j.jaad.2017.12.022
OpenAlex: W2789024274
Cited by: 343
References: 17
Citations by year: 2026: 30 · 2025: 39 · 2024: 40 · 2023: 41 · 2022: 47 · 2021: 64 · 2020: 43 · 2019: 28 · 2018: 10
FWCI: 39.26
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of the American Academy of Dermatology (publishedVersion)
PubMed (publishedVersion)
Funders: Bayer
LEO Pharma
Sanofi
Topics: Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
Keywords: dupilumab, atopic dermatitis, IL-4 receptor alpha antagonist, IL-4/IL-13 signaling, Th2 immune response, topical corticosteroids, biomarkers, adverse events, quality of life, moderate-to-severe atopic dermatitis
MeSH terms: Patient Reported Outcome Measures, Antibodies, Monoclonal, Biological Products, Dermatitis, Atopic, Female, Humans, Male, Quality of Life, Severity of Illness Index, Drug Delivery Systems, Treatment Outcome, Clinical Trials, Phase III as Topic, Risk Assessment, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dupilumab: A review of its use in the treatment of atopic dermatitis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks